An Official Website of the United States Government
TOPIC 229: PHASE I AMPK DEV. OF MOLECULAR PHARMACODYNAMIC ASSAYS
- Small Business Information
-
Woman-Owned: NoMinority-Owned: YesHUBZone-Owned: No
- Phase 1
-
Fiscal Year: 2008Title: TOPIC 229: PHASE I AMPK DEV. OF MOLECULAR PHARMACODYNAMIC ASSAYSAgency: HHSContract: N43CM0800052Award Amount: $149,995.00
Abstract:
AMP-activated protein kinase (AMPK) is a serine/threonine kinase that is a member of a metabolite sensing protein kinase family. AMPK is involved in controlling cellular metabolism and cell proliferation and when activated has been found to be a potent tum or suppressor. Despite a lot of progress in the discovery of therapeutic agents, a pharmacodynamic assay for AMPK is missing. In this proposed research, BioAssay Systems aims to develop a rapid, sensitive, robust and rigorous assay for AMPK activity in tis sue extract. In the Phase I period, BioAssay Systems will select a suitable pan antibody and coat it onto 96-well plates. The immobilized antibody will capture all AMPK protein and isolate it from any potentially interfering enzymes such as other kinases a nd phosphatases. The captured AMPK remains active so that its activity will be directly measured using a fluorescence technology. At the end of the Phase I period, BioAssay Systems will have established experimental conditions and characterized assay perfo rmance including detection limit, reagent stability, reproducibility, variation and accuracy. The SOP of the research pharmacodynamic assay for AMPK will be delivered to NCI. In the Phase II period, BioAssay Systems will further validate the assay in vario us normal and multiple tumor tissues. Studies will be performed to correlate results in tumor versus surrogate tissues such as blood, serum or plasma. Correlation studies will also be compared in human versus laboratory animals (e.g., mouse and rat). This proposal presents a generic platform technology, the successful development and application of which will allow BioAssay Systems to rapidly develop pharmacodynamic assays for other important cancer targets such as kinases, phosphatases and proteases of int erest to NCI.Small Business Information at Submission:Principal Investigator:
Frank HuangBusiness Contact:
BIOASSAY SYSTEMS, LLC
BIOASSAY SYSTEMS, LLC 3423 INVESTMENT BLVD, STE 11 HAYWARD, CA 94545EIN/Tax ID:DUNS: N/ANumber of Employees: N/AWoman-Owned: NoMinority-Owned: NoHUBZone-Owned: No
Award Information
|
Agency: Department of Health and Human Services |
Branch: N/A |
Award ID: 94171 |
Program Year/Program: 2008 / SBIR |
|
Agency Tracking Number: N43CM0800052 |
Solicitation Year: N/A |
Solicitation Topic Code: N/A |
Solicitation Number: N/A |